Monoclonal Antibodies
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
Published in Pharma Law Weekly, October 21st, 2008
Data from two studies presented this week by UCB at the American College of Gastroenterology (ACG) Annual Meeting demonstrate that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate to severe Crohn's disease (CD). A third study presented by UCB provided an estimated comparison of treatment costs and found that CIMZIA offers a cost savings versus other commonly-used biologics.
An analysis of the PRECiSE 3 open-label extension study data showed that after 2.5 years (30 months) of treatment with CIMZIA, 72 percent of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2008-10-21)
More Articles from Pharma Law Weekly
- Aberdeen Australia Equity Fund, Inc.
Aberdeen Australia Equity Fund, Inc. Announces Payment of Quarterly Distribution - Able Forensic Investigations, Inc.
Able Forensic Investigations, Inc. Announces Asset Investigation Techniques Seminars for Law Firms - Addiction Medicine
Research from A. Debruijn et al has provided new information about addiction medicine - AEP Industries Inc.
Court Enters Order Approving AEP Industries Inc.'s Acquisition of Plastic Films Segment of Atlantis Plastics, Inc. - Aetna
Congress, Stakeholders Make History Achieving Mental Health Parity - Allergan
=?ISO-8859-1?Q?TENNIS_CHAMPION_LINDSAY_DAVENPORT_USES_JUV=C9DERM? =?ISO-8859D - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
